Endocrine Abstracts

Radioiodide 131I (RAI) is the therapy of choice for radioiodine-avid differentiated thyroid cancer (DTC). However, 5–15% of DTC patients become RAI refractory (RAIR), and the 10-year survival rate for metastatic disease decreases to 10%. The failure of RAI response is mainly due to the loss of thyroid differentiation, that leads to the loss of expression/function of components of iodide metabolism, first of all the Na/I symporter (NIS). The finding that the MAPK pathway i...